Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients
- 1 January 2015
- journal article
- research article
- Published by Elsevier in Indian Heart Journal
- Vol. 67 (1) , 23-26
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsCirculation, 2014
- Prevalence of Dyslipidemia in Urban and Rural India: The ICMR–INDIAB StudyPLOS ONE, 2014
- A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)Diabetes Technology & Therapeutics, 2014
- A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V)Journal of Diabetes Science and Technology, 2014
- American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive SummaryEndocrine Practice, 2013
- ESC/EAS Guidelines for the management of dyslipidaemiasAtherosclerosis, 2011
- Combination Lipid Therapy in Type 2 DiabetesNew England Journal of Medicine, 2010
- Atherogenic Dyslipidemia: Cardiovascular Risk and Dietary InterventionLipids, 2010
- Dyslipidemia in type 2 diabetes mellitusNature Reviews Endocrinology, 2009
- Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyThe Lancet, 2004